Radiopharm (RADX) Sees Slight Pessimism From Analysts

We recently published 7 Best ASX Stocks to Buy Right Now. Radiopharm Theranostics Limited (NASDAQ:RADX) is one of the best ASX stocks.

Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B. Riley lowered its share price target for the firm to $13 from $15 and kept a Buy rating for the shares on November 26th. As part of its coverage, the research firm discussed Radiopharm Theranostics Limited (NASDAQ:RADX)’s RAD 101 imaging agent and its RAD 204 diagnostic compound. B. Riley explained that the agents have experienced important clinical progress, with RAD101 having shown proof of concept and RAD204’s dose levels being marked as safe.

Radiopharm Theranostics Limited (NASDAQ:RADX) shared its latest update for these programs on October 20th. The firm explained that RAD 204’s phase 1 clinical trial for patients suffering from small cell lung cancer, non-small cell lung cancer, neck cancer, head cancer, and breast cancer showed uptake (absorption) similar to a previous imaging study. Radiopharm Theranostics Limited (NASDAQ:RADX) added that RAD 101 was currently in a Phase 2b clinical trial and had received the FDA’s Fast Track Designation. According to the firm, RAD 101 targets cerebral metastases, and early results of the trial could lead to a global Phase 3 registrational trial. According to Radiopharm Theranostics Limited (NASDAQ:RADX), the market potential for RAD 101 is promising since 300,000 people in the US are diagnosed with cerebral metastases annually.